AOAndrew OwenBSS, MSC, PhD, FSBSlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #35 Can Low-Cost Oral Alternatives Be Used in Place of Oral Lenacapavir When Initiating Long-Acting Lenacapavir PrEP in Low- and Middle-Income Countries? - Andrew OwenView Slideset
VideoHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #16 Inter- and Intraindividual Variability of Long-Acting Cabotegravir/Rilpivirine Pharmacokinetics after 1 Year of Continuous Use - Shawnalyn SunagawaView Video
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #16 Inter- and Intraindividual Variability of Long-Acting Cabotegravir/Rilpivirine Pharmacokinetics after 1 Year of Continuous Use - Shawnalyn SunagawaView Slideset
VideoHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #15 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Virologically Suppressed Adolescents Living with HIV-1 in Sub-Saharan Africa: Data from the LATA Trial - Lisanne BeversView Video
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #15 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Virologically Suppressed Adolescents Living with HIV-1 in Sub-Saharan Africa: Data from the LATA Trial - Lisanne BeversView Slideset
VideoHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #14 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Seminal Plasma throughout the Dosing Interval - Noah NeveretteView Video
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #14 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Seminal Plasma throughout the Dosing Interval - Noah NeveretteView Slideset
VideoHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #13 Intracellular Carbovir- and Lamivudine-Triphosphate Concentrations in PBMC and DBS among Children with HIV-1 Receiving ABC/DTG/3TC: Results from IMPAACT 2019 - Stefanie SchwabView Video
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #13 Intracellular Carbovir- and Lamivudine-Triphosphate Concentrations in PBMC and DBS among Children with HIV-1 Receiving ABC/DTG/3TC: Results from IMPAACT 2019 - Stefanie SchwabView Slideset
VideoHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #12 Pharmacokinetics of Abacavir and Lamivudine in Infants with and without Rifampicin Co-Treatment - Laize BecaView Video
SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #12 Pharmacokinetics of Abacavir and Lamivudine in Infants with and without Rifampicin Co-Treatment - Laize BecaView Slideset
VideoHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #11 A Preliminary Analysis of the Impact of Pharmacogenetic Variation on Bictegravir and Dolutegravir Concentrations in Individuals with HIV and Tuberculosis - Anushka NaidooView Video
